Miglitol

證據等級: L5

預測適應症: 10 個

Miglitol: From Type 2 Diabetes to Type 1 Diabetes Mellitus

One-Sentence Summary

Miglitol is an α-glucosidase inhibitor traditionally used to control postprandial blood glucose in type 2 diabetes mellitus, though it is not currently registered in India. The TxGNN model predicts it may be effective as adjunct therapy for Type 1 Diabetes Mellitus (T1DM) — the highest-evidence indication among all predictions in this pack — supported by 1 completed Phase 3 clinical trial and 16 publications spanning over three decades of research.

Quick Overview

Item	Content
Original Indication	Type 2 Diabetes Mellitus (α-glucosidase inhibitor class; not registered in India)
Predicted New Indication	Type 1 Diabetes Mellitus
TxGNN Prediction Score	99.60%
Evidence Level	L1
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacological information, Miglitol is an α-glucosidase inhibitor that competitively inhibits intestinal brush border enzymes — particularly maltase, sucrase, and starch glucoamylase — delaying the hydrolysis of dietary complex carbohydrates and reducing the rate at which glucose enters the bloodstream after meals. Its efficacy in reducing postprandial hyperglycemia in T2DM is well-established, and this same mechanism is directly applicable to T1DM.

In T1DM, absolute insulin deficiency creates steep postprandial glucose spikes that remain difficult to control even with intensive insulin regimens. A persistent clinical challenge is the pharmacokinetic mismatch between subcutaneous rapid-acting insulin absorption and the rapid surge of meal-derived glucose. By slowing intestinal glucose release, Miglitol can attenuate the peak postprandial glucose load, improve the temporal overlap between insulin action and glucose appearance, and potentially reduce hypoglycemic episodes caused by mistimed or excess insulin boluses.

The key biological insight is that α-glucosidase inhibition acts entirely at the intestinal level — upstream of and independent of insulin secretory capacity. This means the mechanism is equally applicable whether a patient produces abundant insulin (T2DM) or none at all (T1DM), providing a strong and coherent rationale for repurposing.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00213109	Phase 3	Completed	N/A	Direct evaluation of clinical efficacy and safety of Miglitol in T1DM patients treated with insulin — the primary pivotal trial for this repurposing direction
NCT01697592	Phase 3	Completed	585	Omarigliptin add-on in Japanese T2DM patients on oral antihyperglycemic monotherapy; provides regulatory precedent for adjunct oral antidiabetics in Asian populations
NCT02475499	N/A	Completed	886,172	Population-based cohort study assessing incretin-based drugs and pancreatic cancer risk in T2DM across Canada, US, and UK
NCT02456428	N/A	Completed	1,499,650	Multi-centre network study of incretin drugs and heart failure risk in T2DM; cardiovascular safety background for oral antidiabetic combinations
NCT02476760	N/A	Completed	1,417,914	Observational study of incretin drugs and acute pancreatitis risk in T2DM
NCT03492580	N/A	Completed	714,582	Comparative effectiveness of Canagliflozin vs. other antihyperglycemics for heart failure hospitalization and amputation in T2DM
NCT06449235	Phase 4	Not Yet Recruiting	938	Real-world safety and efficacy evaluation of omarigliptin in newly diagnosed T2DM patients in Bangladesh

Literature Evidence

PMID	Year	Type	Journal	Key Findings
2060451	1991	RCT	Diabetes Care	Miglitol delays carbohydrate absorption, improves meal glucose tolerance, and enables more flexible insulin timing in T1DM patients; foundational controlled evidence for this repurposing direction
24843410	2010	Clinical Study	J Diabetes Investigation	Miglitol + insulin combination addresses precipitous postprandial glucose rise uncontrolled by intensive insulin therapy alone; supports clinical utility in T1DM
21869539	2011	Clinical Study	Endocrine Journal	Miglitol 25–50 mg TID with intensive insulin: improved glycemic control, reduced hypoglycemia frequency, and modified incretin hormone responses in 11 T1DM subjects
3311550	1987	Clinical Trial	Clin Pharmacol Ther	Miglitol (Bay-m-1099) allows immediate preprandial insulin injection with ~20% dose reduction while maintaining postprandial control equivalent to insulin given 30 min pre-meal
3286168	1988	Clinical Trial	Diabetes Res Clin Pract	α-Glucosidase inhibition permits flexible insulin timing and reduced dosing in IDDM; directly addresses the clinical challenge of insulin-meal coordination in T1DM
2663321	1989	Clinical Trial	Diabetes Research	Single-blind crossover in 13 IDDM patients: Miglitol significantly reduced area under the glucose curve vs. placebo over 4-week treatment periods
3130257	1988	Clinical Trial	Eur J Clin Investigation	Prolonged administration of BAYm1099 (Miglitol precursor) and BAYo1248 in IDDM: improved glycemic control and reduced insulin requirements confirmed
8261749	1993	Clinical Trial	Diabetic Medicine	Systematic assessment of α-glucosidase inhibition as an adjunct strategy for T1DM management
11460577	2001	Review	Exp Clin Endocrinol Diabetes	Comprehensive review of oral hypoglycemic agents including α-glucosidase inhibitors; reviews mechanism and therapeutic role including insulin-dependent settings
12073790	2002	Review	Rev Med Liège	Pharmacological approaches to postprandial hyperglycemia: Miglitol and acarbose as intestinal glucose absorption modifiers applicable to both T1DM and T2DM

India Market Information

Miglitol currently has no registered products in India and is classified as not marketed. No authorization records are available.

Safety Considerations

Drug Interactions (241 total interactions identified; key moderate-level interactions listed below):

Interacting Drug	Level	Clinical Note
Epinephrine	Moderate	Sympathomimetic used for hypoglycemia reversal — Miglitol may attenuate its glucose-raising effect
Pseudoephedrine	Moderate	Sympathomimetic raises blood glucose; pharmacodynamic antagonism with Miglitol
Phenylephrine	Moderate	Sympathomimetic interaction
Formoterol / Salbutamol	Moderate	Beta-agonists raise blood glucose; pharmacodynamic antagonism
Hydrocortisone / Triamcinolone	Moderate	Corticosteroid-induced hyperglycemia may reduce Miglitol’s glycemic benefit
Hydrochlorothiazide	Moderate	Thiazide diuretics can impair glucose tolerance
Ethanol	Moderate	May potentiate hypoglycemia risk, particularly in T1DM patients concurrently using insulin
Alpelisib	Moderate	PI3K inhibitor causes hyperglycemia; clinically significant pharmacodynamic interaction
Aripiprazole / Asenapine	Moderate	Atypical antipsychotics associated with glucose dysregulation
Ethinylestradiol / Estradiol	Moderate	Hormonal effects on glycemic control
Asparaginase (E. coli / Erwinia)	Moderate	Associated with glucose dysregulation in oncology settings
Acetazolamide	Moderate	Carbonic anhydrase inhibition; glycemic interaction

Please refer to the package insert for key warnings and contraindications, as this data was not available in the current Evidence Pack.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: NCT00213109, a completed Phase 3 trial directly evaluating Miglitol in T1DM patients receiving insulin therapy, combined with over a dozen clinical publications from 1986–2020 across multiple independent research groups, establishes L1-level evidence for this repurposing direction. The mechanistic rationale — insulin-independent postprandial glucose reduction via intestinal α-glucosidase inhibition — is biologically sound and directly applicable to T1DM physiology.

To proceed, the following is needed:

Retrieve the full results of NCT00213109 and evaluate primary endpoints (HbA1c reduction, postprandial glucose excursion, hypoglycemia frequency, insulin dose change)
Obtain detailed MOA data from DrugBank to formally document mechanistic justification (DG002)
Retrieve and review the package insert from a jurisdiction where Miglitol is approved (e.g., US FDA, Japan PMDA) to identify key warnings and contraindications before entering S1 safety evaluation (DG001 — currently Blocking)
Conduct a formal benefit-risk analysis specific to the T1DM population, with particular focus on hypoglycemia risk when Miglitol is used adjunctively with insulin
Define India regulatory pathway and evaluate market entry feasibility given Miglitol’s current zero-registration status in India
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.